|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SIRT5 |
Gene summary for SIRT5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SIRT5 | Gene ID | 23408 |
| Gene name | sirtuin 5 | |
| Gene Alias | SIR2L5 | |
| Cytomap | 6p23 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9NXA8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23408 | SIRT5 | LZE4T | Human | Esophagus | ESCC | 2.66e-07 | 1.67e-01 | 0.0811 |
| 23408 | SIRT5 | LZE7T | Human | Esophagus | ESCC | 1.20e-09 | 5.52e-01 | 0.0667 |
| 23408 | SIRT5 | LZE8T | Human | Esophagus | ESCC | 6.93e-06 | 1.63e-01 | 0.067 |
| 23408 | SIRT5 | LZE22T | Human | Esophagus | ESCC | 3.59e-02 | 2.25e-01 | 0.068 |
| 23408 | SIRT5 | LZE24T | Human | Esophagus | ESCC | 2.71e-09 | 3.59e-01 | 0.0596 |
| 23408 | SIRT5 | LZE6T | Human | Esophagus | ESCC | 3.88e-03 | 1.62e-01 | 0.0845 |
| 23408 | SIRT5 | P1T-E | Human | Esophagus | ESCC | 5.73e-05 | 3.05e-01 | 0.0875 |
| 23408 | SIRT5 | P2T-E | Human | Esophagus | ESCC | 8.72e-16 | 2.69e-01 | 0.1177 |
| 23408 | SIRT5 | P4T-E | Human | Esophagus | ESCC | 8.22e-12 | 2.90e-01 | 0.1323 |
| 23408 | SIRT5 | P5T-E | Human | Esophagus | ESCC | 3.53e-05 | 7.75e-02 | 0.1327 |
| 23408 | SIRT5 | P8T-E | Human | Esophagus | ESCC | 1.80e-10 | 1.85e-01 | 0.0889 |
| 23408 | SIRT5 | P9T-E | Human | Esophagus | ESCC | 2.99e-11 | 2.39e-01 | 0.1131 |
| 23408 | SIRT5 | P10T-E | Human | Esophagus | ESCC | 2.90e-14 | 2.93e-01 | 0.116 |
| 23408 | SIRT5 | P11T-E | Human | Esophagus | ESCC | 4.64e-04 | 2.54e-01 | 0.1426 |
| 23408 | SIRT5 | P12T-E | Human | Esophagus | ESCC | 6.20e-17 | 3.00e-01 | 0.1122 |
| 23408 | SIRT5 | P15T-E | Human | Esophagus | ESCC | 1.63e-18 | 1.88e-01 | 0.1149 |
| 23408 | SIRT5 | P16T-E | Human | Esophagus | ESCC | 2.84e-16 | 2.38e-01 | 0.1153 |
| 23408 | SIRT5 | P17T-E | Human | Esophagus | ESCC | 7.39e-06 | 3.47e-01 | 0.1278 |
| 23408 | SIRT5 | P20T-E | Human | Esophagus | ESCC | 3.44e-09 | 1.45e-01 | 0.1124 |
| 23408 | SIRT5 | P21T-E | Human | Esophagus | ESCC | 3.92e-10 | 1.95e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
| GO:00356015 | Esophagus | ESCC | protein deacylation | 79/8552 | 112/18723 | 8.30e-08 | 1.42e-06 | 79 |
| GO:00987325 | Esophagus | ESCC | macromolecule deacylation | 80/8552 | 116/18723 | 3.19e-07 | 4.50e-06 | 80 |
| GO:00064765 | Esophagus | ESCC | protein deacetylation | 70/8552 | 101/18723 | 1.29e-06 | 1.58e-05 | 70 |
| GO:200037718 | Esophagus | ESCC | regulation of reactive oxygen species metabolic process | 100/8552 | 157/18723 | 3.87e-06 | 4.17e-05 | 100 |
| GO:007259318 | Esophagus | ESCC | reactive oxygen species metabolic process | 137/8552 | 239/18723 | 1.82e-04 | 1.16e-03 | 137 |
| GO:00620129 | Esophagus | ESCC | regulation of small molecule metabolic process | 184/8552 | 334/18723 | 3.11e-04 | 1.85e-03 | 184 |
| GO:00421805 | Esophagus | ESCC | cellular ketone metabolic process | 120/8552 | 211/18723 | 6.70e-04 | 3.55e-03 | 120 |
| GO:20003783 | Esophagus | ESCC | negative regulation of reactive oxygen species metabolic process | 34/8552 | 52/18723 | 3.26e-03 | 1.35e-02 | 34 |
| GO:0006471 | Esophagus | ESCC | protein ADP-ribosylation | 24/8552 | 35/18723 | 5.25e-03 | 1.97e-02 | 24 |
| GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
| GO:00356014 | Oral cavity | OSCC | protein deacylation | 74/7305 | 112/18723 | 5.88e-09 | 1.26e-07 | 74 |
| GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
| GO:00987324 | Oral cavity | OSCC | macromolecule deacylation | 74/7305 | 116/18723 | 5.52e-08 | 1.01e-06 | 74 |
| GO:00064764 | Oral cavity | OSCC | protein deacetylation | 66/7305 | 101/18723 | 7.36e-08 | 1.30e-06 | 66 |
| GO:200037716 | Oral cavity | OSCC | regulation of reactive oxygen species metabolic process | 92/7305 | 157/18723 | 4.96e-07 | 7.27e-06 | 92 |
| GO:00421804 | Oral cavity | OSCC | cellular ketone metabolic process | 111/7305 | 211/18723 | 3.94e-05 | 3.45e-04 | 111 |
| GO:007259316 | Oral cavity | OSCC | reactive oxygen species metabolic process | 122/7305 | 239/18723 | 9.73e-05 | 7.34e-04 | 122 |
| GO:20003782 | Oral cavity | OSCC | negative regulation of reactive oxygen species metabolic process | 31/7305 | 52/18723 | 2.08e-03 | 9.59e-03 | 31 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SIRT5 | SNV | Missense_Mutation | rs765381829 | c.131G>A | p.Arg44Gln | p.R44Q | Q9NXA8 | protein_coding | tolerated(0.13) | possibly_damaging(0.679) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SIRT5 | SNV | Missense_Mutation | c.520N>C | p.Glu174Gln | p.E174Q | Q9NXA8 | protein_coding | tolerated(0.32) | benign(0.015) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| SIRT5 | SNV | Missense_Mutation | c.844N>G | p.Thr282Ala | p.T282A | Q9NXA8 | protein_coding | tolerated(0.05) | possibly_damaging(0.76) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SIRT5 | SNV | Missense_Mutation | rs547625145 | c.358N>A | p.Ala120Thr | p.A120T | Q9NXA8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SIRT5 | SNV | Missense_Mutation | rs550780850 | c.884N>T | p.Thr295Met | p.T295M | Q9NXA8 | protein_coding | deleterious(0.02) | benign(0.175) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
| SIRT5 | SNV | Missense_Mutation | rs765381829 | c.131N>A | p.Arg44Gln | p.R44Q | Q9NXA8 | protein_coding | tolerated(0.13) | possibly_damaging(0.679) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SIRT5 | SNV | Missense_Mutation | novel | c.61N>T | p.Pro21Ser | p.P21S | Q9NXA8 | protein_coding | tolerated_low_confidence(0.37) | benign(0.001) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SIRT5 | SNV | Missense_Mutation | rs771260132 | c.401N>A | p.Arg134Gln | p.R134Q | Q9NXA8 | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SIRT5 | SNV | Missense_Mutation | novel | c.359C>T | p.Ala120Val | p.A120V | Q9NXA8 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SIRT5 | SNV | Missense_Mutation | novel | c.661N>A | p.Val221Met | p.V221M | Q9NXA8 | protein_coding | deleterious(0.03) | probably_damaging(0.995) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 23408 | SIRT5 | ENZYME | GNF-PF-1720 | CHEMBL578329 | ||
| 23408 | SIRT5 | ENZYME | OLEOYL DOPAMINE | OLEOYL DOPAMINE | ||
| 23408 | SIRT5 | ENZYME | CEFIXIME | CEFIXIME | ||
| 23408 | SIRT5 | ENZYME | inhibitor | 252827480 | ||
| 23408 | SIRT5 | ENZYME | NSC-74859 | CHEMBL477936 | ||
| 23408 | SIRT5 | ENZYME | SURAMIN | SURAMIN | 25818461,23195732 | |
| 23408 | SIRT5 | ENZYME | GW7647 | GW7647 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |